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Evaluating changes in radiation treatment
volumes from post-operative to same-day
planning MRI in High-grade gliomas
Colin E Champ1*, Joshua Siglin1, Mark V Mishra1, Xinglei Shen1, Maria Werner-Wasik1, David W Andrews2,
Sonal U Mayekar1, Haisong Liu1 and Wenyin Shi1

Abstract
Background: Adjuvant radiation therapy (RT) with temozolomide (TMZ) is standard of care for high grade gliomas
(HGG) patients. RT is commonly started 3 to 5 weeks after surgery. The deformation of the tumor bed and brain
from surgery to RT is poorly studied. This study examined the magnitude of volume change in the postoperative
tumor bed and the potential impact of RT planning.
Method and materials: This study includes 24 patients with HGG who underwent craniotomy and adjuvant RT
with TMZ at our institution. All patients had immediate postoperative MRI and repeat MRI during the day of RT
simulation. Gross tumor volumes (GTV), clinical target volumes (CTV) of initial 46 Gy (CTV1) and boost to 60 Gy
(CTV2) were contoured on both sets of MRIs according to RTOG (Radiation Therapy Oncology Group) guidelines.
For patients who recurred after RT, the recurrence pattern was evaluated.
Results: An average of 17 days elapsed between immediate and delayed MRIs. GTV1 (FLAIR abnormality and tumor
bed) decreased significantly on the delayed MRI as compared to immediate post-operative MRI (mean = 30.96cc,
p = 0.0005), while GTV2 (contrast-enhanced T1 abnormality and tumor bed) underwent a non-significant increase
(mean = 6.82cc, p = 0.07). Such changes lead to significant decrease of CTV1 (mean decrease is 113.9cc, p<0.01),
and significant increase of CTV2 (mean increase is 32.5cc, p=0.05). At a median follow-up of 13 months, 16 patients
(67%) progressed, recurred, or died, with a progression-free survival time of 13.7 months. Twelve patients failed
within all CTVs based on immediate and delayed MRIs, while one patient recurred outside of CTV2 based on
immediate post-operative MRI, but within the CTV2 defined on delayed MRI.
Conclusion: The postoperative tumor bed of HGGs undergoes substantial volumetric changes after surgery.
Treatment planning based on delayed MRI significantly reduces the volume of treated brain tissue without local
control detriment. The marked reduction of volume treated to 46 Gy based on delayed MRI scan, could result in
increased sparing of organs at risk. There may be a small risk of inadequate radiation field design if radiation
planning is based on immediate post-operative MRI.
Keywords: High-grade glioma, Radiotherapy planning, Same-day MRI, Glioblastoma multiforme,
Anaplastic astrocytoma
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Background
High-grade gliomas (HGG), including World Health
Organization (WHO) grade III anaplastic astrocytoma
(AA) and grade IV glioblastoma multiforme (GBM),
occur in approximately 5 cases per 100,000 people in the
US. HGG are the most frequently occurring gliomas,
with GBM comprising 53.7% of all new cases and AA
accounting for 6.7% [1].
Maximum safe resection is standard initial treatment for
HGG, and the extent of resection is correlated with
improved outcomes [2]. Several studies have shown that
post-operative radiation therapy (RT) alone or combined
with chemotherapy improves survival in HGG [3,4]. RT
was historically delivered via a whole brain approach. However, Shapiro et al. showed equivalence in survival in
patients treated with whole brain RT to 43 Gray (Gy) with
a cone-down to 60 Gy, resulting in a shift in treatment
paradigm [5]. Further retrospective data from M.D.
Anderson for HGG supported the efficacy of reduced field
RT [6]. This approach is further supported by patterns of
failure studies which, using combinations of biopsy, brain
computed tomography (CT), brain magnetic resonance imaging (MRI), and autopsy information, have uniformly indicated that the predominant failure pattern for HGG
patients is within a 2-cm margin of the tumor volume [7-9].
Given the use of reduced field, conformal RT, it is becoming increasingly important to accurately delineate the
post-operative tumor bed. Recent standards for RT for
HGG as denoted in Radiation Therapy Oncology Group
(RTOG) 0825 guidelines recommend use of a CT-based
simulation merged to a pre or post-operative MRI [10].
Guidelines on radiation target volume delineation remain
unclear with some authors advocating for smaller margins
than those described in the protocol [11,12]. In addition,
guidelines on optimal timing of planning MRI are limited
as well. The recommended starting time for radiation is
3-5 weeks (21–35 days) after surgery [10]. The brain deformation and change in the tumor bed during this time
period is poorly understood. We hypothesized that large
changes in the tumor bed and T2/FLAIR abnormality
would occur between the time of surgery and initiation of
RT. Therefore, a delayed MRI at the time of RT planning
may more accurately reflect the tumor bed at time of RT,
and potentially allow us to spare more normal tissue with
no decrease in local tumor control. The purpose of this
study was to prospectively evaluate the changes in treatment volumes between immediate post-operative MRI
and same-day MRI at time of RT planning in an attempt
to spare more normal tissue.

Page 2 of 8

MRI (within 48 hours) to assess the extent of resection. We
prospectively obtained a delayed MRI, which was performed at the time of RT planning, on 24 consecutive
patients from July 19, 2010 to June 13, 2011, with pathologically confirmed HGG treated at our institution in an
Institutional Review Board (IRB) approved protocol. All
patients underwent craniotomy with resection or biopsy
and were treated with temozolomide during RT and after.
All data and medical records were reviewed comprehensively in accordance with the Health Insurance Portability
and Accountability Act, our institutional IRB, and with
the Helsinki Declaration of 1975, as revised in 2000.
Contoured tumor volumes and treatment

Patients were simulated in the supine position with an
aquaplast head mask. CT scan without intravenous contrast was obtained on a GE LightSpeed CT simulator
(GE Healthcare, Chalfont St. Giles, UK) and 2.5-mm
slices were obtained. Immediate post-operative MRI was
obtained within 48 hours after craniotomy. Same-day
MRI was obtained on the day of treatment planning. All
patients underwent thin-cut, 1-1.5 mm slice thickness
MRI imaging, including pre- and post-contrast T1weighted and T2/FLAIR sequences. All images sets were
imported into Elekta Focal Treatment Planning Software
(Version 4.3.1, Stockholm, Sweden) and fused.
Target volume delineation was based on planning CT
fusion with immediate and delayed MRI images. This provided us with fused images with high spatial fidelity (CT)
and anatomic resolution (all MRI pulse sequences) upon
which we could base target volume paired comparisons as
well as design optimal treatment plans. The initial volume
received a dose of 46 Gy. The initial gross tumor volume
(GTV1) was defined as tumor bed and T2/FLAIR abnormality. Clinical tumor volume 1 (CTV1) was GTV1 with
a 2-cm expansion, modified to avoid barriers of spread
(i.e. bone, falx cerebri, ventricles). Planning tumor volume
1 (PTV1) was a CTV1 with a 0.5-cm uniform expansion.
GTV2, which is the boost volume to 60 Gy, was defined
as tumor bed and T1 post-contrast enhancement. CTV2
was a 2-cm uniform expansion of GTV2, modified to
avoid barriers of spread. PTV2 was a 0.5-cm uniform expansion of CTV2. All the contours were generated on
both immediate and delayed MRIs. All contours were
done by a single operator (C.C.) and confirmed by two
expert observers (W.S. and J.S.) in order to limit interobserver variability. Both the operator and observers
were blinded to whether the MRIs were post-operative
or delayed and the MRIs were presented in a random
manner to reduce recall bias.

Methods
Study population

Power calculation

At our institution, all patients with HGG who undergo surgical resection and biopsy have immediate postoperative

After retrospectively reviewing and calculating mean volume changes in 5 patients treated at our institution, and
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based on an estimated standard deviation of 25%, we
required 24 patients to detect a difference of 30% in the
CTV treatment volume with a two-sided hypothesis test
at the 0.05 level of significance. These values were calculated at initial study design.
Data analysis

Current RT treatment guidelines for HGG in RTOG
protocols and many US institutions depend largely on
T2/FLAIR and T1 post-contrast enhancement which led
us to analyze target changes over time defined by these
two standard pulse sequences. Treatment margins are
based solely on these MRI findings and we set out to
elucidate any changes between scans occurring in the
immediate post-operative period and those at the time
of treatment planning, often occurring 2-4 weeks after
craniotomy. Student’s paired t-test was performed to
compare the post-operative and delayed treatment
volumes.
Recurrence patterns at interim analysis were then
compared by fusion of the recurrence MRI with both
treatment plans and all corresponding images. Recurrence was assessed individually on surveillance MRI.
The site of recurrence was contoured on planning
software and then compared with each blinded treatment MRI. Progression-free survival time was calculated using the Kaplan-Meier (KM) method. Location
of recurrence within GTV1/2 and CTV1/2 based on
post-operative MRI were compared to these volumes
based on same-day MRI. Recurrence was based primarily on surveillance MRIs, which are reviewed at
our weekly multidisciplinary brain tumor conference
involving members from several institutional departments, including radiation oncology, neuro-oncology,
neurosurgery, and neuroradiology. Biopsy-proven recurrence is not required in our institution if it is felt
that imaging results show unequivocal progression by
consensus of the board. Student’s paired t-test was performed to compare recurrence patterns between postoperative and delayed treatment volumes.
Statistical analyses were performed using the Stata
Statistical package (version IC 11.1, Texas). Logistic regression was performed to identify patient and tumor
variables predicting for a >30% change in CTV between
the post-operative MRI and delayed MRI for both T1
and T2/FLAIR imaging sequences. Variables included in
the analysis were steroid usage (dexamethasone), tumor
histology, and extent of resection (gross total, subtotal,
and biopsy). P-value of less than 0.05 was considered
statistically significant.

Results
In total, 16 patients with GBM and 8 with AA were
included in the analysis. The median age at the initiation
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of RT was 57 years old (range 22-78). Please refer to
Table 1 for patient characteristics. Treatment-planning
CT scans of the brain were obtained a median of 17 days
after craniotomy (range 7-32) and merged with immediate and delayed MRI for planning (see Table 2). While
our institution generally prefers treatment planning
2 weeks after craniotomy in an effort to initiate treatment during postoperative week 3, this was not always
possible due to extenuating patient circumstances.

Volumetric analysis

There were significant changes in both T1 postcontrast enhancement and T2/FLAIR abnormality from
immediate post-operative MRI to delayed MRI scans
in all patients. T2/FLAIR-based GTV1 decreased in
23 patients, with an average decrease of 22.1% (mean =
30.96cc, range -140.15 to -0.33, p = 0.0005). CTV1 had
a 16.9% average decrease in volume (mean = 113.86cc,
range -347.70 to 36.73, p = 0.000003).
Table 1 Patient demographics
Patient Age Histology

Location

Surgery *Dexamethasone
treatment

1

52

AA

(R) Parietal

STR

No

2

56

AA

(L) Parietal

GTR

Yes

3

58

AA

(L) Temporal

STR

No

4

64

AA

(L) Temporal

STR

No

5

70

AA

(R) Temporal

STR

Yes

6

22

AA

(R) Frontal

STR

Yes

7

36

AA

(L) Frontal

GTR

Yes

8

59

AA

(L) Frontal

GTR

No

9

56

GBM

(L) Parietal

STR

No

10

78

GBM

(R) Parietal

STR

No

11

61

GBM

(L) Temporal

STR

Yes

12

59

GBM

(L) Parietal

STR

Yes

13

70

GBM

(R) Temporal

BX

Yes

14

48

GBM

(L) Frontal

STR

No

15

49

GBM

(R) Frontal

STR

Yes

16

66

GBM

(L) Temporal

STR

No

17

66

GBM

(R) Temporal

STR

Yes

18

50

GBM

(R) Frontal

GTR

No

19

46

GBM

(L) Temporal

STR

Yes

20

87

GBM

(R) Frontal

STR

No

21

35

GBM

(R) Thalamus

STR

No

22

75

GBM

(L) Frontal

STR

Yes

23

54

GBM

(R) Frontal

STR

Yes

24

52

GBM

(L) Frontal

STR

No

Abbreviations: AA Anaplastic astrocytoma, GBM Glioblastoma multiforme, STR
Subtotal resection, GTR Gross total resection, BX Biopsy, L Left, R Right, *At
time of MRI.
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Table 2 Treatment volumes
MRI Span (Days)

GTV1 Δ

%

GTV2 Δ

%

CTV1 Δ

%

CTV2 Δ

%

1

8

-40.7

42

6.9

37

-139.4

26

37.9

16

2

10

-0.3

1

5.2

35

-13

5

18.2

8

3

7

-16.4

35

3

26

-77

20

16

8

4

15

-3.9

2

6.6

67

-49.9

5

47.6

26

5

19

-19.7

14

13.9

25

-49.4

7

33.9

7

6

26

-25.9

37

-17

37

-125.1

26

-89.8

24

7

17

-10.1

7

-5

4

-93.1

12

-35.8

6

8

13

-2.4

36

-0.3

14

-27.5

17

-3.4

3

9

13

-12.4

27

3.3

44

-83.1

20

15.1

22

10

27

-21.8

33

1.9

31

-154.6

23

18

12

11

17

-52.7

34

22

39

-195.9

24

198.8

83

12

11

-12.4

18

2.2

7

-69.4

14

1.4

0

13

15

-14.3

16

22.6

37

-16.9

3

136.9

31

14

16

36.9

60

16.2

107

184.9

24

85.8

37

15

12

-35.8

31

-10.8

27

-95.8

18

-43

12

16

32

-72

63

-0.2

1

-282.8

42

45.2

16

17

14

-130.9

54

14.6

20

-347.7

34

64.4

12

18

28

-35.5

44

1.8

6

-160.3

31

-14.6

5

19

16

11.6

100

-13.4

54

36.7

13

-5.1

3

20

19

-140.1

56

6.3

19

-300.6

28

31

9

21

31

-17

13

-10.6

9

-101.1

14

-82.2

12

22

22

-2

3

-2

21

-10.1

2

-10.5

6

23

14

-5.2

3

73.3

121

-27

3

249.4

51

24

16

-46.3

26

19.4

36

-164.6

19

65.4

16

Average

17

-31

22

6.8

22

-113.9

17

32.5

12

Patient

Abbreviations: Post-op Post-operative, MRI Magnetic resonance imaging, GTV1 Gross tumor volume treated to 46 Gy, CTV1 Clinical tumor volume treated to 46 Gy,
GTV2 Gross tumor volume treated to 60 Gy, CTV2 Clinical tumor volume treated to 60 Gy, (-) values indicate volume was smaller on same-day MRI, (+) values
indicate volume was larger on delayed MRI.

T1 post-contrast enhancement-based GTV2 underwent an average increase of 22% (mean = 6.82cc, range
-13.44 to 73.26, p = 0.07). This resulted in a 12% increase of CTV2 (mean = 32.52cc, range -89.83 to
249.45, p = 0.05). Thirteen patients in total had a 30% or
greater increase in GTV1 (n= 9/16 GBM patients), while
11 patients had a 20% or greater increase in CTV1
(n=8/16 GBM patients, n= 3/8 AA patients). Several
lesions had a striking change in size, including a CTV2
increase of 83% (Figure 1C and D), a CTV2 increase of
51% (Figure 2), and a CTV1 decrease of 42%; all were
GBMs.
In subgroup analysis, AA GTV1 volume underwent
a 16% decrease (mean = 14.94cc, range 0.33 to 40.73,
p = 0.02). CTV1 decreased by 13% (mean = 71.81cc,
range -12.96 to -139.43, p = 0.002). However, changes
in GTV2 (5%, mean = 1.67cc, range 0.30 to 16.96,
p = 0.63) and CTV2 (1%, mean = 3.05cc, range -89.83
to 47.60, p = 0.86) were non-significant.

In contrast, GTV1 for GBM patients underwent broad
fluctuations in the post-operative and delayed GTV
volumes, with a decrease in volume of 32.82% (mean =
38.97cc, range 23.19 to 189.32, p = 0.003). Similarly in
significance, CTV1 decreased by an average of 20.01%
(mean = 134.88cc, range -300.64 to 36.73, p = 0.0008).
GTV2 underwent lesser changes that trended toward
significance, with an increase of 23.44% (mean = 9.40cc,
range -13.44 to 73.26, p = 0.09). CTV2 reached statistical significance with an increase in size by 14.43%
(mean = 47.25cc, range -82.18 to 249.50, p = 0.05).
When comparing volume changes with steroid usage,
tumor histology, and type of resection, no significant
effects in treatment volume were appreciated when logistic regression was performed.
Recurrence patterns

At a median follow-up of 13 months, 16 patients progressed or died. One patient recurred distantly and 2
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Figure 1 Changes in volume on T2/FLAIR and T1 contrast-enhanced MRI: A. T2/FLAIR MRI performed 1 day after craniotomy. B. T2/
FLAIR MRI performed 2 weeks after craniotomy. Another patient with C. T1 contrast-enhanced MRI performed 1 day after craniotomy. D. T1
contrast-enhanced MRI performed 2 weeks after craniotomy.

died with no sign of progression. Progression-free survival time was 13.7 months, on KM analysis (Figure 3).
Failure was within CTV1 and CTV2 based on both
immediate and delayed imaging in 86% of patients
(n=12/14). One patient failed outside of CTV2 based
on immediate post-operative MRI only and no patients
failed outside of CTV1 or CTV2 based on same-day
imaging. This was not statistically significant (p=0.34).
Though not significant, 46% of patients (n=6) failed
outside of one or more GTV volumes on postoperative MRI and 39% of patients (n=5) failed outside
of one or more GTV on same-day MRI (p=0.35).

Discussion
Long term survival of patients with HGG remains poor
due to local recurrence after treatment, with the vast
majority occurring within a 2-cm area of the presurgical
tumor margin, emphasizing the importance of accurately
defined treatment volumes [7-9]. Guidelines for treatment planning have been evolving in recent RTOG protocols, which are used as guidelines for treatment
planning by many institutions within the US and internationally. While the recent RTOG 0825 protocol
required CT-based planning for RT with post-operative
MRI fusion to ensure accurate target delineation, only
three years earlier RTOG 0525 used pretreatment MRIs

for treatment planning [10]. While CT often displays the
surgical tumor bed, MRI presents the planning physician
with further tools to elucidate tumor bed and surrounding edema [13]. Contrast-enhanced T1 MRI best evaluates residual tumor and areas of blood–brain barrier
breakdown, while T2/FLAIR enhancement best evaluates
tissue edema [14,15].
Our data shows that the CTV1, including the resection cavity and surrounding edema, changes extensively
in both GBM and AA patients in the small time interval
between surgery and RT planning, with same-day planning MRI elucidating a more accurate representation of
the lesion and decrease in surgical edema. CTV2 also
changed significantly for combined AA and GBM, but
only for GBM patients on subset analysis. Twenty-three
of 24 CTV1 volumes decreased in size within an average
of 17 days between post-operative MRI and treatment
planning MRI. This decrease in size can potentially spare
proximal organs at risk and spares normal brain tissue
from being treated to the initial dose of 46 Gy. In contrast, CTV2 increased in size in 16 of 24 patients, which
could potentially result in improved tumor bed coverage
during the treatment boost in comparison to immediate
post-operative MRI. Nearly a third of all patients had
over a 25% change in CTV2 with planning MRI performed in 17 days or less after craniotomy, including
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Figure 2 Changes of GTV on T2/FLAIR and contrast-enhanced MRI: A. GTV2 on post-operative T1 contrast-enhanced MRI. B. GTV2 on
delayed T1 contrast-enhanced MRI, C. GTV1 on post-operative T2/FLAIR MRI. D. GTV1 on delayed T2/FLAIR MRI.

2 patients with a greater than 50% change in their
volumes.
Our data also shows that treating with RT based on
same-day MRI does not result in increased rates of
tumor recurrence outside of the treatment volume, as
no failures were seen outside of the CTV volumes based
on same-day MRI. In fact, only one patient had disease
recurrence locally which was outside of CTV based on
post-operative imaging only. Therefore, while less

Figure 3 Progression-free survival.

volume of tissue is irradiated when planning is based on
same-day MRI versus immediate post-operative MRI, it
is unlikely that treatment based on same-day MRI
results in an increase in tumor-miss. These changes
could result in alterations in treatment volumes, resulting in a large impact for future RTOG and other protocols, which may be based on imaging sets that do not
accurately define the tumor bed volume.
Similar findings regarding volume changes were presented at the 2010 American Society for Radiation Oncology Annual Meeting, revealing large variations in
surgical cavities with both expansion and shrinkage occurring mostly within the first two weeks after craniotomy for HGG patients. This group of investigators also
demonstrated a benefit in local control and a decrease in
radiation injury in patients with planning MRI delayed
for over two weeks [16]. While we cannot determine a
benefit in local control as the aggressive nature of these
tumors results in frequent local recurrence, it appears
that when MRI is delayed over two weeks, normal tissue
can be spared with no detriment on local control.
While RTOG 0825 has a clear set of guidelines concerning treatment margins, some practitioners advocate
tighter margins [11,12]. However, when reviewing our
data, caution should be employed with this technique as
it introduces the potential of missing gross tumor, as our
data indicates that GTV increases even in the short time
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period between post-operative and same-day MRI, timing of MRI may become more important for practitioners of limited-margin treatment to limit the
possibility of tumor miss.
While we have shown that the resection cavity undergoes extensive volumetric changes in the short interval
between surgical resection and RT planning, several
studies have illustrated volumetric changes throughout
treatment. Shukla et al. have shown that at week 5 of
treatment, 12/15 patients with unifocal disease had a
median reduction of 54.85cc in tumor volumes on T2weighted MRI [17]. As a result, they suggest midtreatment re-planning MRI, potentially to define boost
fields. Tsien et al. prospectively followed 21 patients
who were rescanned at week 3 during RT [18]. They
found an increase in GTV in 3/12 patients with GBM,
with all cases requiring increase in size of treatment
fields. A multi-institutional trial examining volume
changes midway through treatment of GBMs showed a
change in GTV in 80% of cases [19]. Given the increasing impetus to reduce treatment volumes recently, further research in this area may be warranted.
It is possible that the treatment volume undergoes several changes as the resection space contracts, surrounding edema waxes and wanes, and the actual tumor
volume changes, and no minimal amount of reasonable
reimaging could monitor this change. While the decrease in treatment volume seen on T2/FLAIR imaging
in our study was likely from a reduction in peri-tumor
edema, the increase in GTV2 was somewhat unexpected. This change may represent evolution of blood
products, principally methemoglobin, post-operative
changes which have been documented to occur between
days 5 and 14 post-operatively, and/or tumor progression [20]. Optimal imaging times remain unknown but
target volumes may be least ambiguous after 14 days
postoperatively. As a result, we recommend that the
MRI used to define the planning volume should be
delayed to the time of CT simulation, with the treatment
to start as soon as possible to reduce the potential for
further changes that might negatively impact the effectiveness of treatment.

Conclusions
The results of this study illustrate the changes that the
post-operative tumor bed of high-grade gliomas undergoes prior to RT and the important effect on target delineation during treatment planning. The marked
reduction of volume treated to 46 Gy based on sameday versus post-operative MRI may result in better sparing of normal brain tissue without a detriment in local
control. Additionally, the increased CTV2 volume may
result in better tumor coverage, avoiding potential geographic miss in treatment based on immediate post-
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operative MRI scan. Given the differences demonstrated
in treatment volume at varying MRI time points, further
attempts should be made to correlate treatment planning with patterns of failure to maximize local control
while minimizing toxicity.
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